US FDA tightens regulations for use of erythopoiesis-stimulating agents

被引：0
作者：
不详
机构：
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：483 / 483
页数：1
相关论文
共 50 条
  • [21] Use of agents stimulating erythropoiesis in digestive diseases
    Moreno Lopez, Rosario
    Sicilia Aladren, Beatriz
    Gomollon Garcia, Fernando
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (37) : 4675 - 4685
  • [22] Developments in the therapeutic use of erythropoiesis stimulating agents
    Jelkmann, Wolfgang
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (03) : 287 - 297
  • [23] Preclinical studies conducted on nanozyme antioxidants: shortcomings and challenges based on US FDA regulations
    Ghorbani, Milad
    Izadi, Zhila
    Jafari, Samira
    Casals, Eudald
    Rezaei, Foroogh
    Aliabadi, Alireza
    Moore, Alycia
    Ansari, Ali
    Puntes, Victor
    Jaymand, Mehdi
    Derakhshankhah, Hossein
    NANOMEDICINE, 2021, 16 (13) : 1133 - 1151
  • [24] US FDA panel backs wider use of rosuvastatin
    不详
    EJHP PRACTICE, 2010, 16 (01): : 14 - 14
  • [25] US FDA panel backs wider use of rosuvastatin
    不详
    EJHP PRACTICE, 2010, 16 (02): : 14 - 14
  • [26] US FDA announces launch of Safe Use Initiative
    Reactions Weekly, 2009, 1278 (1) : 1 - 1
  • [27] US FDA restricts codeine and tramadol use in children
    Reactions Weekly, 2017, 1649 (1) : 6 - 6
  • [28] Agents at the Peak of US FDA Approval for the Treatment of Alzheimer's Disease
    Alam, Jahngeer
    Kalash, Anushka
    Hassan, Md Imtaiyaz
    Rahman, Syed Ziaur
    NEUROLOGICAL RESEARCH, 2024, 46 (04) : 318 - 325
  • [29] US FDA requests warnings for micro-bubble contrast agents
    Reactions Weekly, 2007, 1174 (1) : 3 - 3
  • [30] Clinical use of the erythropoietin stimulating agents: defining the risks
    Kosmidis, Paris A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S155 - S156
12345